Introduction
============

Agoraphobia is considered to be the most serious complication of panic disorder. According to the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Text Revision (DSM-IV-TR),[@b1-ppa-5-575]--[@b3-ppa-5-575] agoraphobia is a progressive development of debilitating anxiety symptoms related to being in situations where one would be extremely embarrassed and could not be rescued in the case of a panic attack.

The typical constellation of agoraphobic symptoms emerges in specific circumstances[@b4-ppa-5-575] such as being out of the house alone or in the midst of many unknown people, waiting in line, navigating a bridge or tunnel, or traveling by car, bus, plane, or train. Furthermore, other less common manifestations of agoraphobia such as the need to wear sunglasses, carry items such as a bottle of water or anti-anxiety medications, or being unable to wear a turtleneck, necktie, or even a ring have been described.[@b5-ppa-5-575] Therefore, an agoraphobic person tends to avoid places and/or situations that may induce a panic attack, and, if the individual must be in these situations, they experience extreme discomfort and the conviction of an imminent panic attack.[@b5-ppa-5-575] In many affected individuals, this develops into an uncontrollable need to use a "companion guide" -- defined as a trusted person, usually a friend or relative -- to cope with the more common acts of normal social life. Although agoraphobia is a complication/ consequence of panic disorder, the DSM-IV-TR also describes agoraphobia without a history of panic disorder. This condition is difficult to assess but it seems to affect between 0.6% and 6% of the general population, especially women.[@b1-ppa-5-575],[@b6-ppa-5-575],[@b7-ppa-5-575] However, it is widely believed that agoraphobia is always preceded by panic attacks, which may be triggered by specific, well-demonstrated factors or may be subthreshold[@b8-ppa-5-575] with an atypical manifestation. According to this conceptual approach, panic disorder always begins with recurrent, unexpected panic attacks, which occur in typical neurovegetative form due to activation of the locus coeruleus,[@b9-ppa-5-575]--[@b11-ppa-5-575] less frequently, and bio-electrical desynchronization of the temporal lobes, causing depersonalization--derealization panic-related syndrome. In the next stage, the complex of anticipatory and intercritical anxiety arises, caused by persistent limbic activation. Finally, agoraphobia develops, supported by a progressive pattern of cortical processing, fear, and avoidance.

Pharmacologic treatment of panic disorder and anticipatory and intercritical anxiety with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors has excellent results. However, agoraphobia remains largely refractory to these approaches, and only sporadic and inconclusive data support the effectiveness of cognitive behavioral psychotherapy.[@b12-ppa-5-575]--[@b17-ppa-5-575] Therefore, this study aimed to investigate the efficacy of noninvasive brain stimulation using a radioelectric asymmetric conveyor (REAC) for agoraphobia.

Materials and methods
=====================

Patients
--------

Twenty-three patients (3 males, 20 females) participated in this study. Mean age of onset was 29.4 ± 2.4 years, mean age when diagnosis was made was 36.6 ± 1.8 years, and age range was 34--41 years. Patients were referred to our institute with a diagnosis of agoraphobia without a history of panic disorder. All patients were evaluated by a psychiatrist according to DSM-IV-TR criteria[@b2-ppa-5-575],[@b3-ppa-5-575],[@b18-ppa-5-575] and all were assessed using the Agoraphobia Scale (AS).[@b19-ppa-5-575]

The AS
------

The AS[@b19-ppa-5-575] is a self-administered questionnaire and consists of 20 items divided into two sections that describe common agoraphobic situations. Since anxiety can be present in absence of avoidance and (more rarely) vice versa, the first section of this psychometric instrument captures the anxiety parameters and is rated from 0 (no anxiety) to 4 (extreme anxiety). The second section captures the avoidance parameters and is rated from 0 (absent avoidance) to 2 ( constant avoidance). The AS was administered in this study by a team of psychiatrists at baseline screening (t0) and about 1 month after the end of the first (t1) and second (t2) cycles of noninvasive brain stimulation. The AS is easy for the patient to complete and takes about 10 minutes.

The REAC device
---------------

The REAC[@b20-ppa-5-575],[@b21-ppa-5-575] is a medical biostimulation device based on innovative technology. The model used in this study (Convogliatore di Radianza Modulante; ASMED, Florence, Italy) is specific for noninvasive brain stimulation techniques.

Patients underwent noninvasive brain stimulation REAC treatment, according to the standardized protocol of neuro-psycho-physical-optimization (NPPO). The REAC-NPPO treatment protocol consisted of seven radio frequency bursts of 500 milliseconds each at a frequency of 10.5 GHz and with a specific absorption rate of 7 μW/kg, applied by touching the metallic tip of the REAC probe to the pavilion of the ear. REAC treatment has proven efficacy in ameliorating several stress-related disorders,[@b22-ppa-5-575]--[@b26-ppa-5-575] as well as depression,[@b26-ppa-5-575]--[@b28-ppa-5-575] anxiety,[@b26-ppa-5-575],[@b28-ppa-5-575] bipolar disorder,[@b29-ppa-5-575] and some forms of dementia.[@b30-ppa-5-575]

The REAC treatment protocol for this study consisted of two 18-session cycles of brain stimulation applied to the ear. In every session, seven specific points of the pavilion of the ear were stimulated, and this noninvasive and painless procedure lasted about 3.5 seconds. The first REAC treatment cycle was separated from the following cycle by an interval of about 6 months.

Statistical analysis
--------------------

Two statistical tests, the Wilcoxon signed-rank test and the Sign test, were used to compare the mean and standard deviation of all AS items for anxiety and for avoidance between pairs of timepoints (t1 and t0; t2 and t0; t2 and t1). Variation in AS item scores was used to determine which items showed low, medium, and good responses to REAC treatment.

Results
=======

At baseline (t0), the average total AS score for all items ([Table 1](#t1-ppa-5-575){ref-type="table"}) for "anxiety" was 3.3 ± 0.3, corresponding to a "severe" clinical picture, while the average total score for all items relating to "avoidance" was 1.5 ± 0.3, indicating strong and very frequent avoidant behavior. Approximately 1 month after the end of the first cycle (t1) of REAC-NPPO therapy, the average total AS score of all the items for "anxiety" decreased slightly, to 2.8 ± 1.6, corresponding to a clinical picture pathologically less important than that observed at t0, but not significant from a statistical point of view, at least in general terms. In fact, the relative score for "anxiety" for some items such as 1, 20, and 3 were significantly reduced.

The same holds with regard to the average total AS score for all the items for "avoidance" reduced to 1.3 ± 0.4, although, also in this case, the abovementioned items were significantly decreased. Approximately 1 month after the end of the second cycle (t2) of REAC-NPPO therapy, the average total AS score for all the items for "anxiety" decreased significantly, to 2.4 ± 0.4, and the average total AS score for all the items for "avoidance" also decreased significantly, to 0.9 ± 0.2. Furthermore, with respect to t0, some items showed an even greater statistical significance, especially for "avoidance": specifically, items 1, 20, and 3.

Globally, in the comparison between t2 and t0, item-by-item analysis showed a weak response to treatment for anxiety ([Table 2](#t2-ppa-5-575){ref-type="table"}) and avoidance ([Table 3](#t3-ppa-5-575){ref-type="table"}) on item 7. A moderate response was observed for items 10 and 13. A good, statistically significant response was observed for items 1--6, 9, 11, 12, and 14--20.

Discussion
==========

The current results highlight the potential of REAC brain stimulation for the treatment of complex and chronic clinical conditions such as agoraphobia that are typically resistant to current pharmacologic treatments. The relatively rapid therapeutic effect, appearing in just a few months, highlights important time and economic advantages, even in comparison with novel cognitive behavioral treatment strategies. In general terms, the anxiety component of this clinical condition improved from very severe and pervasive to limited severity, and the avoidance component improved from disabling to subthreshold and manageable picture. Therefore, on the basis of clinical observation and the reductions in total AS scores, the response to REAC-NPPO therapy appears to be very favorable. It is interesting to note that, compared with previous studies published on bipolar disorder,[@b29-ppa-5-575] panic disorder,[@b27-ppa-5-575] generalized anxiety disorder,[@b25-ppa-5-575],[@b26-ppa-5-575],[@b28-ppa-5-575] Alzheimer's disease,[@b30-ppa-5-575] and various stress-related disorders,[@b22-ppa-5-575]--[@b26-ppa-5-575] the response of agoraphobia to REAC-NPPO therapy was slower and less robust, as significant improvement on anxiety and avoidance was not present at the first timepoint (t1). One possible explanation for this could be that agoraphobia may be a secondary complication of the primary disorder (ie, panic disorder) and would therefore be less affected by treatment, similar to the effects of treatment on alcohol dependence in an individual with social anxiety disorder. Another explanation could be that the long interval of time between the onset and diagnosis of agoraphobia delays the first therapeutic attempt. This critical delay may favor establishment of neuroanatomical circuitry that supports agoraphobic thoughts and related avoidant behaviors. Finally, agoraphobia without symptoms of panic disorder does not usually appear suddenly and severely; rather, it subtly insinuates itself, gradually influencing thoughts and attitudes and preventing an individual from mobilizing appropriate defense strategies. However, as previously noted, some AS items had already improved after the first cycle of REAC-NPPO therapy. This suggests that qualitative analysis of clinical data is justified to determine the health status of the individual. Using this approach, the majority of the patients felt globally better after the first cycle of REAC-NPPO therapy, and this effect was close to statistical significance. After the second cycle of treatment, the improvement from baseline was more evident. In fact, one of the most interesting features of REAC-NPPO is the enhancement in efficacy observed across repeated cycles. In addition and according to our experience about this peculiar kind of brain stimulation, it is important to discontinue therapy for a period of 4--6 months. This interval may allow a sort of "deep reorganization" (optimization) of brain and/or mental functions, as with agoraphobia, where the tendency to avoid harm overcomes other survival parameters, such as novelty seeking and reward dependence.

Conclusion
==========

Although this was an open-label, naturalistic study conducted on a small number of patients, it was the first study to explore the potential of brain stimulation in a clinical disorder such as agoraphobia, a disorder with no clear organic framework. The refractory nature of agoraphobia to current treatments, combined with the great suffering and progressive functional impairment of patients, necessitates development of new therapeutic strategies to promote social rehabilitation. The unique, noninvasive brain stimulation achieved by REAC appears very promising because of its high tolerability and good safety profile.

Clearly, considering the obvious limitations, more rigorous studies should investigate the effects of REAC in double-blind, placebo-controlled designs in a larger sample to determine the potential of this approach for agoraphobia and other, similar conditions. Furthermore, since agoraphobia is a chronic condition, longer observation periods are needed; this may also help to reduce any possible and nonspecific positive role that can be produced through the enthusiasm of being subjected to an innovative treatment technology.

**Disclosure**

Salvatore Rinaldi and Vania Fontani are the inventors of the REAC.

###### 

Agoraphobia Scale items

  Item   Description
  ------ ---------------------------------------------------------------------------------
  1      Being alone in your home
  2      Shopping unaccompanied in small shops (eg, a grocery, pharmacy, etc)
  3      Crossing a street in the city alone
  4      Being in a crowd unaccompanied
  5      Traveling on a bus unaccompanied, when it is crowded
  6      Walking straight across large open spaces in the city (eg, a square)
  7      Driving a car alone through a long tunnel
  8      Walking away from your home alone
  9      Traveling by train or underground unaccompanied, when it is crowded
  10     Standing unaccompanied in a long queue in a post office, bank, supermarket, etc
  11     Sitting on a chair for a long time, when in the company of other people
  12     Eating at a restaurant or café
  13     Sitting in the middle of a row at a cinema or theater
  14     Shopping unaccompanied in a department store that is full of people
  15     Walking over a bridge when there are a lot of people and traffic about
  16     Driving a car alone over a bridge
  17     Having a haircut at the hairdresser, unaccompanied
  18     Shopping unaccompanied in a large supermarket, crowded with people
  19     Walking in a crowded street unaccompanied
  20     Riding in an elevator unaccompanied

###### 

Agoraphobia Scale: anxiety

  Item                                    Average change (%)   Statistical test                                                                                                               
  --------------------------------------- -------------------- ------------------ ------- -------------- -------------- -------------- ---------------------------------------------- ------- ----------------------------------------------
  **Significant response to treatment**                                                                                                                                                       
  1                                       64.10                74.36              28.57   −4.28; 0.000   −4.33; 0.000   −4.28; 0.000   0.000                                          0.000   0.008
  2                                       22.37                72.37              64.41   −3.69; 0.000   −4.33; 0.000   −3.69; 0.000   0.000                                          0.000   0.000
  3                                       66.67                74.36              23.08   −4.28; 0.000   −4.33; 0.000   −4.28; 0.034   0.000                                          0.000   0.063
  4                                       22.37                72.37              64.41   −3.37; 0.001   −4.33; 0.000   −3.37; 0.000   0.001                                          0.000   0.000
  5                                       22.37                73.68              66.10   −3.49; 0.000   −4.33; 0.000   −3.49 0.000    0.000                                          0.000   0.000
  6                                       21.33                72.00              64.41   −2.96; 0.003   −4.29; 0.000   −2.96; 0.000   0.003                                          0.000   0.000
  8                                       21.33                72.00              64.41   −3.02; 0.000   −4.32; 0.000   −4.32; 0.000   0.001                                          0.000   0.000
  9                                       22.37                73.68              66.10   −3.49; 0.000   −4.31; 0.000   −4.39; 0.000   0.000                                          0.000   0.000
  11                                      22.37                73.68              66.10   −3.49; 0.000   −4.33; 0.000   −4.34; 0.000   0.000                                          0.000   0.000
  12                                      22.37                72.37              64.41   −3.69; 0.000   −4.36; 0.000   −4.32; 0.000   0.000                                          0.000   0.000
  14                                      23.38                72.73              64.41   −3.22; 0.001   −4.31; 0.000   −4.32; 0.000   0.001                                          0.000   0.000
  15                                      22.37                73.68              66.10   −3.49; 0.000   −4.33; 0.000   −4.34; 0.000   0.000                                          0.000   0.000
  16                                      25.32                73.42              64.41   −3.54; 0.000   −4.33; 0.000   −4.32; 0.000   0.000                                          0.000   0.000
  17                                      22.37                73.68              66.10   −3.54; 0.000   −4.27; 0.000   −4.39; 0.000   0.000                                          0.000   0.000
  18                                      22.37                72.37              64.41   −3.22; 0.001   −4.27; 0.000   −4.32; 0.000   0.001                                          0.000   0.000
  19                                      36.84                73.68              58.33   −4.32; 0.000   −4.33; 0.000   −4.46; 0.000   0.000                                          0.000   0.000
  20                                      55.26                72.37              38.24   −4.17; 0.000   −4.27; 0.000   −3.36; 0.001   0.000                                          0.000   0.000
  **Moderate response to treatment**                                                                                                                                                          
  10                                      22.37                72.37              64.41   −2.76; 0.006   −3.36; 0.001   −2.00; 0.046   0.004                                          0.000   0.125
  13                                      66.67                74.36              23.08   −3.22; 0.001   −3.46; 0.001   −2.24; 0.025   0.001                                          0.000   0.063
  **Low response to treatment**                                                                                                                                                               
  7                                       1.28                 2.56               1.30    −1.00; 0.317   −1.41; 0.157   −1.00; 0.317   NR[\*](#tfn1-ppa-5-575){ref-type="table-fn"}   0.500   NR[\*](#tfn1-ppa-5-575){ref-type="table-fn"}

**Note:** Sign test algorithm gave no response value in this instable case.

**Abbreviations:** Asymp Sig, asymptotic significance (two-tailed); Exact Sig, exact significance (two-tailed); NR, no response.

###### 

Agoraphobia Scale: avoidance

  Item                                    Average change (%)   Statistical test                                                                                                               
  --------------------------------------- -------------------- ------------------ ------- -------------- -------------- -------------- ---------------------------------------------- ------- ----------------------------------------------
  **Significant response to treatment**                                                                                                                                                       
  1                                       64.10                74.36              28.57   −4.28; 0.000   −4.33; 0.000   −4.28; 0.000   0.000                                          0.000   0.008
  2                                       22.37                72.37              64.41   −3.69; 0.000   −4.33; 0.000   −3.69; 0.000   0.000                                          0.000   0.000
  3                                       66.67                74.36              23.08   −4.28; 0.000   −4.33; 0.000   −4.28; 0.034   0.000                                          0.000   0.063
  4                                       22.37                72.37              64.41   −3.37; 0.001   −4.33; 0.000   −3.37; 0.000   0.001                                          0.000   0.000
  5                                       22.37                73.68              66.10   −3.49; 0.000   −4.33; 0.000   −3.49 0.000    0.000                                          0.000   0.000
  6                                       21.33                72.00              64.41   −2.96; 0.003   −4.29; 0.000   −2.96; 0.000   0.003                                          0.000   0.000
  8                                       21.33                72.00              64.41   −3.02; 0.000   −4.32; 0.000   −4.32; 0.000   0.001                                          0.000   0.000
  9                                       22.37                73.68              66.10   −3.49; 0.000   −4.31; 0.000   −4.39; 0.000   0.000                                          0.000   0.000
  11                                      22.37                73.68              66.10   −3.49; 0.000   −4.33; 0.000   −4.34; 0.000   0.000                                          0.000   0.000
  12                                      22.37                72.37              64.41   −3.69; 0.000   −4.36; 0.000   −4.32; 0.000   0.000                                          0.000   0.000
  14                                      23.38                72.73              64.41   −3.22; 0.001   −4.31; 0.000   −4.32; 0.000   0.001                                          0.000   0.000
  15                                      22.37                73.68              66.10   −3.49; 0.000   −4.33; 0.000   −4.34; 0.000   0.000                                          0.000   0.000
  16                                      25.32                73.42              64.41   −3.54; 0.000   −4.33; 0.000   −4.32; 0.000   0.000                                          0.000   0.000
  17                                      22.37                73.68              66.10   −3.54; 0.000   −4.27; 0.000   −4.39; 0.000   0.000                                          0.000   0.000
  18                                      22.37                72.37              64.41   −3.22; 0.001   −4.27; 0.000   −4.32; 0.000   0.001                                          0.000   0.000
  19                                      36.84                73.68              58.33   −4.32; 0.000   −4.33; 0.000   −4.46; 0.000   0.000                                          0.000   0.000
  20                                      55.26                72.37              38.24   −4.17; 0.000   −4.27; 0.000   −3.36; 0.001   0.000                                          0.000   0.000
  **Moderate response to treatment**                                                                                                                                                          
  10                                      22.37                72.37              64.41   −2.76; 0.006   −3.36; 0.001   −2.00; 0.046   0.004                                          0.000   0.125
  13                                      66.67                74.36              23.08   −3.22; 0.001   −3.46; 0.001   −2.24; 0.025   0.001                                          0.000   0.063
  **Low response to treatment**                                                                                                                                                               
  7                                       1.28                 2.56               1.30    −1.00; 0.317   −1.41; 0.157   −1.00; 0.317   NR[\*](#tfn3-ppa-5-575){ref-type="table-fn"}   0.500   NR[\*](#tfn3-ppa-5-575){ref-type="table-fn"}

**Note:** Sign test algorithm gave no response value in this instable case.

**Abbreviations:** Asymp Sig, asymptotic significance (two-tailed); Exact Sig, exact significance (two-tailed); NR, no response.
